Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

Ahmad Nanaa; Rong He; James M. Foran; Talha Badar; Naseema Gangat; Animesh Pardanani; William J. Hogan; Mark R. Litzow; Mrinal Patnaik; Aref Al-Kali; Hassan B. Alkhateeb

doi:10.1111/bjh.19105

Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

Ahmad Nanaa, Rong He, James M. Foran, Talha Badar, Naseema Gangat, Animesh Pardanani, William J. Hogan, Mark R. Litzow, Mrinal Patnaik, Aref Al-Kali, Hassan B. Alkhateeb

Research output: Contribution to journal › Article › peer-review

Abstract

Venetoclax (VEN) is an FDA-approved selective inhibitor of B-cell leukaemia/lymphoma-2 (BCL-2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high-risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41-mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.

Original language	English (US)
Pages (from-to)	171-176
Number of pages	6
Journal	British journal of haematology
Volume	204
Issue number	1
DOIs	https://doi.org/10.1111/bjh.19105
State	Published - Jan 2024

Keywords

DDX41
hypomethylating agents
response
treatment
venetoclax

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.19105

Cite this

Nanaa, A., He, R., Foran, J. M., Badar, T., Gangat, N., Pardanani, A., Hogan, W. J., Litzow, M. R., Patnaik, M., Al-Kali, A., & Alkhateeb, H. B. (2024). Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. British journal of haematology, 204(1), 171-176. https://doi.org/10.1111/bjh.19105

Nanaa, A, He, R, Foran, JM, Badar, T, Gangat, N, Pardanani, A , Hogan, WJ , Litzow, MR , Patnaik, M, Al-Kali, A & Alkhateeb, HB 2024, 'Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients', British journal of haematology, vol. 204, no. 1, pp. 171-176. https://doi.org/10.1111/bjh.19105

@article{cdbe827fbf554aae94414fbe4b714ce4,

title = "Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients",

abstract = "Venetoclax (VEN) is an FDA-approved selective inhibitor of B-cell leukaemia/lymphoma-2 (BCL-2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high-risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41-mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.",

keywords = "DDX41, hypomethylating agents, response, treatment, venetoclax",

author = "Ahmad Nanaa and Rong He and Foran, {James M.} and Talha Badar and Naseema Gangat and Animesh Pardanani and Hogan, {William J.} and Litzow, {Mark R.} and Mrinal Patnaik and Aref Al-Kali and Alkhateeb, {Hassan B.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2024",

month = jan,

doi = "10.1111/bjh.19105",

language = "English (US)",

volume = "204",

pages = "171--176",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome

T2 - Mayo Clinic series on 12 patients

AU - Nanaa, Ahmad

AU - He, Rong

AU - Foran, James M.

AU - Badar, Talha

AU - Gangat, Naseema

AU - Pardanani, Animesh

AU - Hogan, William J.

AU - Litzow, Mark R.

AU - Patnaik, Mrinal

AU - Al-Kali, Aref

AU - Alkhateeb, Hassan B.

PY - 2024/1

Y1 - 2024/1

N2 - Venetoclax (VEN) is an FDA-approved selective inhibitor of B-cell leukaemia/lymphoma-2 (BCL-2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high-risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41-mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.

AB - Venetoclax (VEN) is an FDA-approved selective inhibitor of B-cell leukaemia/lymphoma-2 (BCL-2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high-risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41-mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.

KW - DDX41

KW - hypomethylating agents

KW - response

KW - treatment

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85170840626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170840626&partnerID=8YFLogxK

U2 - 10.1111/bjh.19105

DO - 10.1111/bjh.19105

M3 - Article

C2 - 37710381

AN - SCOPUS:85170840626

SN - 0007-1048

VL - 204

SP - 171

EP - 176

JO - British journal of haematology

JF - British journal of haematology

IS - 1

ER -

Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this